Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, net loss was USD 2.11 million compared to USD 3.25 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.